• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION RANGER PACLITAXEL-COATED PTA BALLOON CATHETER; DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLASTY CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION RANGER PACLITAXEL-COATED PTA BALLOON CATHETER; DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLASTY CATHETER Back to Search Results
Model Number 1973-03
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Obstruction/Occlusion (2422); Arteriosclerosis/ Atherosclerosis (4437)
Event Date 05/18/2023
Event Type  Injury  
Event Description
Elegance clinical study.It was reported that restenosis occurred, requiring revascularization.On 09-aug-2022, the subject underwent treatment with this 6.0 x 200mm, 150cm ranger paclitaxel-coated pta balloon catheter and 6x80, 130 cm eluvia drug-eluting vascular stent system as part of the elegance clinical trial.The target lesion was in the right proximal superficial femoral artery (sfa), right mid-sfa, extending up to right distal sfa with 5 mm proximal reference vessel diameter, and 5 mm distal reference vessel diameter, with lesion length 200 mm with 100% stenosis, and was classified as transatlantic intersociety consensus (tasc) ii d lesion.Prior to the target lesion treatment with the study device, atherectomy was performed, and pre-dilation was performed by using a 3 mm x 25 mm non-boston scientific percutaneous transluminal angioplasty (pta) balloon, a 4 mm x 220 mm pta balloon, a 5 mm x 200 mm pta balloon, and a 5 mm x 120 mm pta balloon.Treatment of the target lesion was then performed by dilation using the study devices, this 6 mm x 200 mm ranger drug coated balloon, and a 6 mm x 80 mm eluvia drug eluting stent.Post-dilation was performed using a 5 mm x 60 mm pta balloon, and the final residual stenosis was noted to be 10%.On 10-aug-2022, the subject was discharged from the hospital on dual antiplatelet therapy.On 18-may-2023, the subject was referred for bilateral lower extremity arterial duplex due to claudication and history of right sfa stent left iliac stent.Bilateral lower extremity arterial duplex was performed which revealed on the right side: more than 75% stenosis the proximal sfa, and calcification in external iliac, common femoral, mid-sfa and distal sfa, deep femoral, popliteal, posterior tibial, peroneal, anterior tibial and dorsalis pedis which was consistent with less than 50% stenosis.On 16-nov-2023, the subject presented to the hospital for peripheral angiogram and possible intervention of the right lower extremity due to complaints of progressively worsening right leg pain for the past one year.On the same day, abdominal aortogram revealed mild atherosclerotic changes of the distal abdominal aorta with no significant obstructive disease, the right ileo-femoral artery system was patent with no significant disease, patent right internal iliac artery, left common iliac artery stent was patent with no angiographic evidence of restenosis, patent left external iliac artery with no significant disease, occluded left internal iliac artery.Selective angiography of the right lower extremity revealed patent common femoral artery with no significant obstructive disease, occluded proximal sfa, occluded sfa at distal segment, patent deep femoral artery and extensive collaterals that reconstitute the right popliteal artery with three-vessel run off to the periphery.On the same day, occlusion noted in the right proximal sfa, right mid-sfa, and right distal sfa.These were treated using atherectomy and thrombectomy devices followed by dilation using balloon and drug coated balloon.Post treatment, the final residual stenosis was noted to be 5%.On the same day, the event was considered to be resolved.
 
Manufacturer Narrative
A1 patient identifier: (b)(6).A2 patient age: 66 years old at time of enrollment.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RANGER PACLITAXEL-COATED PTA BALLOON CATHETER
Type of Device
DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLASTY CATHETER
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
HEMOTEQ AG
adenauerstrasse 15
wuerselen 52146
GM   52146
Manufacturer Contact
rachel shields
4100 hamline ave n
arden hills, MN 55112
6512422111
MDR Report Key18318441
MDR Text Key330382066
Report Number2124215-2023-70175
Device Sequence Number1
Product Code ONU
UDI-Device Identifier08714729976202
UDI-Public08714729976202
Combination Product (y/n)Y
Reporter Country CodeUS
PMA/PMN Number
P190019
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 12/13/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date02/02/2024
Device Model Number1973-03
Device Catalogue Number1973-03
Device Lot Number01100H22
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 11/27/2023
Initial Date FDA Received12/13/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/02/2022
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Treatment
JETSTREAM, STERLING PTA, ELUVIA.
Patient Outcome(s) Required Intervention;
Patient SexFemale
Patient RaceBlack Or African American
-
-